Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nebivolol
Drug ID BADD_D01541
Description Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity.[A182579] Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol].[A182579] Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics.[A182594] Nebivolol was granted FDA approval on 17 December 2007.[L7985]
Indications and Usage For the treatment of essential hypertension.
Marketing Status Prescription; Discontinued
ATC Code C07AB12
DrugBank ID DB04861
KEGG ID D05127
MeSH ID D000068577
PubChem ID 71301
TTD Drug ID D0Z1UA
NDC Product Code 51407-485; 13668-355; 65977-0048; 51407-484; 72241-035; 59651-138; 50090-5761; 31722-588; 71209-058; 62559-275; 31722-587; 67877-392; 62559-276; 59651-139; 72241-032; 27241-179; 27241-182; 51407-486; 71209-059; 71209-061; 51407-483; 0904-7225; 50090-5708; 50090-5752; 67877-391; 67877-390; 62559-278; 0904-7190; 31722-585; 27241-181; 0904-7226; 13668-353; 50090-5775; 72241-034; 71209-060; 67877-393; 13668-354; 27241-180; 31722-586; 13668-356; 59651-137; 72241-033; 62559-277; 59651-140; 0904-7189
Synonyms Nebivolol | Alpha,Alpha'-(Iminobis(Methylene))bis(6-Fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol | Bystolic | Nebilet | Silostar | Nebivolol Hydrochloride | Hydrochloride, Nebivolol | R 67555 | 67555, R | R-67555 | R67555 | Lobivon
Chemical Information
Molecular Formula C22H25F2NO4
CAS Registry Number 99200-09-6
SMILES C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dizziness17.02.05.003; 02.01.02.004; 24.06.02.0070.001192%
Drug abuse19.07.02.0100.000124%Not Available
Drug hypersensitivity10.01.01.0010.002145%Not Available
Dyspepsia07.01.02.0010.000477%
Dyspnoea22.02.01.004; 02.01.03.0020.002145%
Epistaxis24.07.01.005; 22.04.03.0010.000477%
Erythema23.03.06.0010.000477%Not Available
Fatigue08.01.01.0020.001668%
Feeling abnormal08.01.09.0140.000715%Not Available
Feeling cold08.01.09.0080.000477%Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Headache17.14.01.0010.002383%
Heart rate decreased13.14.04.0010.002145%Not Available
Heart rate irregular13.14.04.0030.000477%Not Available
Hepatic function abnormal09.01.02.001--Not Available
High density lipoprotein decreased13.12.01.003--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hypersensitivity10.01.03.0030.002145%
Hypersensitivity vasculitis24.05.02.012; 23.06.02.005; 10.02.02.017; 01.01.04.008--Not Available
Hypertension24.08.02.0010.002622%
Hypertensive crisis24.08.01.0010.000477%Not Available
Hypotension24.06.03.0020.000953%
Influenza like illness08.01.03.0100.000477%
Insomnia19.02.01.002; 17.15.03.002--
Intermittent claudication24.04.03.001--Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.000477%Not Available
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Muscle spasms15.05.03.0040.000715%
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages